Invesco Biotechnology & Genome ETF
PBE
73 hedge funds and large institutions have $129M invested in Invesco Biotechnology & Genome ETF in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
40% more capital invested
Capital invested by funds: $92.6M → $129M (+$36.7M)
22% more funds holding
Funds holding: 60 → 73 (+13)
1.41% less ownership
Funds ownership: 32.49% → 31.08% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$4.41M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.23M |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$3.41M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$3.31M |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.87M |
| 2 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$632K |
| 3 |
PFG
Pacific Financial Group
Bellevue,
Washington
|
-$274K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$259K |
| 5 |
B
Baird
Milwaukee,
Wisconsin
|
-$210K |
PBE Hedge Fund Activity: Q1 2014 in Review
73 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2014, worth a combined $129M — up 40% from $92.6M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PBE positions and 7 closed out — a net gain of 13 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $4.41M. The largest seller was Morgan Stanley, cutting an estimated $6.87M.
- 73 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2014, up from 60 in Q4 2013.
- Funds reported $129M of Invesco Biotechnology & Genome ETF stock for Q1 2014, up 40% quarter-over-quarter.
- 20 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2014 and 7 closed out, a net change of +13 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2014 was Jane Street, an estimated $4.41M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2014 was Morgan Stanley, an estimated $6.87M sold.
Based on aggregated 13F filings for Q1 2014.